South Korea's finance ministry will allow the withdrawal of foreign banknotes exchanged from Korean currency automated teller machines in convenience stores beginning next year to ease regulations in the foreign exchange market.
Under the move, banks may be asked to exchange the Korean won for foreign bills via smartphone applications with the foreign currencies being available for withdrawal at convenience stores.
The ministry will soon coordinate with convenience store operators about the proposed set up.
The regulation is among the five announced by the ministry, which includes foreign tourists allowing to receive sent money at an ATM and applications for exchanges on insurance company apps.
The objective is to allow remittance network sharing.
The foreign exchange transaction regulations were revised to increase innovation based on more competition and to minimize face-to-face activities.


Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



